Blog

Depo Provera lawsuits are active in MDL No. 3140 in the Northern District of Florida. Plaintiffs allege that repeated or long-term use of the birth control shot raised the risk of intracranial meningioma, a tumor that forms around the brain or spinal cord. They also claim Pfizer and other drug companies failed to give doctors and patients a clear warning. The defendants deny liability and maintain that the medicine is safe and effective when used as directed.

Thousands of federal claims are now part of the coordinated litigation. Court records also refer to progress toward a global agreement, but it has not resolved every case. No official payout chart applies to every claimant. This article reviews the current lawsuit status, medical research, FDA warning, claim evidence, settlement factors, and legal deadlines.

Current Depo Provera Lawsuit Status

Federal Depo Provera claims are part of MDL No. 3140 in the U.S. District Court for the Northern District of Florida. Judge M. Casey Rodgers oversees the coordinated pretrial process. The Judicial Panel on Multidistrict Litigation created the MDL on February 7, 2025, because the cases share questions about meningioma risk, product warnings, and safer alternatives.

Official JPML data listed 5,508 pending actions and 5,590 historical actions in MDL 3140 on June 1, 2026. An MDL does not turn every claim into one class action. It places similar federal cases before one judge for discovery, expert evidence, and common legal issues. Each plaintiff still has an individual injury history and personal claim.

A June 15, 2026 court order said eligible plaintiffs would have an opportunity to resolve their claims through a global agreement once it becomes final. That order also made clear that the agreement would not resolve every case. The current public court calendar lists continued case management conferences and a Rule 702 expert hearing on September 18, 2026.

Claims at the Center of the Cases

Plaintiffs claim that repeated Depo Provera injections raised the risk of intracranial meningioma. They also argue that the warning did not clearly explain this possible danger. Other claims may include negligence, defective design, and breach of warranty.

Pfizer and other defendants deny liability and say the medicine is safe when used as directed. Each claimant must prove product use, diagnosis, causation, and damages. Medical history, length of use, tumor type, and expert evidence may affect the case.

Research Behind the Meningioma Concern

A 2024 study in The BMJ reviewed 18,061 women who had surgery for intracranial meningioma and compared them with 90,305 controls. It found a link between prolonged use of injectable medroxyprogesterone acetate and meningioma surgery. The reported odds ratio was about 5.6, but only a small number of patients in that group had used the medicine.

The study does not prove that Depo Provera caused every tumor or that every user faces a high risk. Researchers found the clearest link after long-term use, not short-term exposure. The findings later became part of a wider medical and legal review of progestogen medicines.

The research supports further review, but every case still depends on its own medical and legal evidence.

FDA Warning and Patient Safety

The FDA updated the Depo Provera label in December 2025 to include a warning about meningioma after repeated and long-term use. Healthcare professionals should watch for possible signs and stop the medicine if a patient receives a meningioma diagnosis.

Depo Provera also carries a boxed warning about bone mineral loss and is not usually advised beyond two years unless other options do not work. Patients should not stop birth control based only on online claims. A doctor can review the risks, suggest another method, and assess any serious neurological symptoms.

Possible meningioma symptoms can include:

• Headaches that become frequent or change over time
• Seizures or unexplained loss of awareness
• Blurred vision, double vision, or other sight changes
• Hearing loss or ringing in one ear
• Weakness or numbness in an arm or leg
• Memory, speech, balance, or personality changes

Meningiomas may grow slowly and cause no early signs. Symptoms also depend on the location and size of the tumor. These problems can have several causes, so a symptom alone does not prove that a person has meningioma or that a medicine caused it.

Depo Provera and Depo SubQ Are Different

Depo Provera CI usually refers to a 150 mg intramuscular injection. Depo-subQ Provera 104 uses a lower dose and is given under the skin. Federal lawsuits discuss these products separately because plaintiffs claim the lower-dose option should have received greater attention as a possible alternative.

This claim remains part of the litigation and does not prove that one product caused an injury or that another option was safe for every patient. Product name, dose, injection method, and manufacturer may still matter when old treatment records are reviewed.

Evidence Used in Depo Provera Claims

A person may need proof of Depo Provera or generic medroxyprogesterone acetate use, such as clinic, pharmacy, insurance, or billing records. Lawyers may review the number of shots, treatment length, dates, and product maker. A confirmed intracranial meningioma diagnosis is also important and may require MRI, CT, surgery, pathology, or specialist records. Current claims mainly focus on meningioma rather than common side effects or headaches without a diagnosis.

Common records for a case review may include:

• Depo Provera prescription or injection records
• Pharmacy, clinic, and insurance claim history
• MRI and CT reports
• Hospital and surgical records
• Pathology results
• Treatment bills and insurance statements
• Employment records that show lost income
• Notes about symptoms and recovery
• Details about other hormone medicines

No single checklist guarantees eligibility. State law, product identity, diagnosis date, exposure history, and medical evidence can change the result. The federal court has required threshold proof of both product use and injury in the MDL, which shows the importance of reliable records at an early stage.

Factors That May Affect a Settlement

No official Depo Provera payout chart applies to every plaintiff. The court has confirmed a global agreement process, but no fixed payment or total settlement amount is public. Websites that promise a certain payout should be viewed with care.

Case value may depend on surgery, seizures, vision loss, lasting nerve problems, treatment costs, lost income, and future care. A small tumor that only needs scans may have a different value from a claim that involves major surgery or permanent harm.

Short-term use, missing records, another diagnosis, or other risk factors may weaken a case. Legal fees, case costs, medical liens, and other deductions can reduce the final recovery and may differ between cases.

How Depo Provera Claims Move Through Court

A case review often starts with questions about when Depo Provera use began, how long it continued, and when the tumor was found. A lawyer may then request medical, pharmacy, clinic, or insurance records. A federal claim may enter MDL 3140 through direct filing or transfer, but the court does not automatically approve every case.

State deadlines can limit how long a person has to file. The time may depend on the diagnosis date and when the possible link became known. Claimants should keep copies of all records and confirm whether a case has been filed, which defendants are named, and which court handles it.

Conclusion

Depo Provera litigation now involves thousands of federal claims tied to alleged meningioma injuries. Medical research found an association with prolonged injectable medroxyprogesterone acetate use, and the FDA added a meningioma warning to the U.S. label in December 2025. Those facts support further review, but they do not prove every individual claim.

A strong case review depends on clear injection records, a confirmed diagnosis, medical evidence, and timely legal action. Anyone with health concerns should speak with a licensed medical professional. Anyone who needs advice about a possible lawsuit should consult a qualified product liability lawyer. This article provides general information and does not replace medical or legal advice.

Common Questions